PolyPid Secures Landmark $320M+ Deal for Breakthrough Infection Drug

PETACH TIKVA, Israel – July 21, 2026 – In a move that signals a major shift in the fight against postoperative complications, Israeli biopharmaceutical firm PolyPid has entered into an exclusive partnership with Azurity Pharmaceuticals. The deal, potentially worth over $320 million, is centered on the U.S. and Canadian commercialization of D-PLEX₁₀₀, a novel drug designed to prevent surgical site infections (SSIs), a persistent and costly challenge in modern healthcare.

This landmark agreement not only provides a clear commercial pathway for PolyPid’s lead asset but also marks the company's pivotal transition from a clinical-stage innovator to a commercial-stage enterprise. For Azurity, a private global pharmaceutical company, the deal adds a highly differentiated, late-stage asset to its portfolio, leveraging its specialized commercial infrastructure to tackle a significant unmet medical need.

A Transformative Financial Lifeline

The financial architecture of the agreement provides PolyPid with a substantial and immediate infusion of non-dilutive capital, shoring up its balance sheet and validating its proprietary drug delivery technology. Under the terms, PolyPid will receive an upfront payment of $15 million upon signing, with an additional $15 million milestone payment due upon the anticipated U.S. Food and Drug Administration (FDA) acceptance of the D-PLEX₁₀₀ New Drug Application (NDA) in August 2026.

Beyond these initial payments, the deal structure includes up to approximately $300 million in potential payments tied to regulatory, development, and sales-based milestones. Furthermore, once D-PLEX₁₀₀ hits the market, PolyPid is set to receive tiered royalties on net sales in the U.S. and Canada, ranging from the mid-teens to the mid-twenties. The company will also retain worldwide manufacturing rights, supplying the finished product to Azurity at a transfer price that includes an embedded margin, adding another revenue stream.

For a small-cap biotech company whose market capitalization hovered around $100 million before the announcement, the deal's total potential value is transformative. It provides a funded runway to not only support the launch of D-PLEX₁₀₀ but also to reinvest in its core technology platform and advance its broader pipeline.

“This partnership is a defining step in PolyPid’s transition into a commercial-stage company, and Azurity is the right partner to bring D-PLEX₁₀₀ to U.S. and Canadian patients, hospitals and surgeons,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “Importantly, this collaboration represents a meaningful validation of our unique platform, and allows us to fully realize the U.S. and Canadian commercial value of D-PLEX₁₀₀ while putting us in a position of financial strength to continue investing in our Kynatrix technology, pipeline, and the next generation of therapies.”

Targeting a Critical Unmet Need in Surgical Care

The strategic importance of D-PLEX₁₀₀ stems from the pervasive and dangerous problem it aims to solve. Surgical site infections are one of the most common and costly healthcare-associated infections, complicating up to 30% of certain surgical procedures. In the United States alone, they contribute an estimated $3.5 billion to $10 billion in annual healthcare costs, driven by prolonged hospital stays, re-admissions, and the need for additional, often complex, medical interventions.

Despite stringent hygiene protocols and the use of prophylactic antibiotics, SSIs remain a major cause of postoperative morbidity and mortality. D-PLEX₁₀₀ is designed to address this gap directly at the source. It employs PolyPid’s proprietary Kynatrix™ delivery technology, a polymer-lipid-based matrix that encases the broad-spectrum antibiotic doxycycline. Administered directly into the surgical wound before closure, the matrix is designed to provide a prolonged, controlled release of the antibiotic for up to 30 days, maintaining a high local concentration to eradicate residual bacteria while minimizing systemic exposure and associated side effects.

The drug's potential was powerfully demonstrated in its pivotal Phase 3 SHIELD II trial. The study, focused on patients undergoing abdominal colorectal surgery with large incisions, successfully met its primary endpoint and, crucially, demonstrated a 60% relative risk reduction in the incidence of SSIs compared to the standard of care. This robust clinical evidence underpins the FDA's decision to grant D-PLEX₁₀₀ Breakthrough Therapy Designation, a status reserved for drugs that may demonstrate substantial improvement over available therapy for serious conditions.

The Strategic Synergy of Science and Commerce

While PolyPid brings the scientific innovation, Azurity brings the commercial muscle—a synergy that both companies believe is key to market success. Azurity has built its reputation by commercializing specialized therapies, employing what it calls a “first-in-class commercial model” that uses data and digital tools to efficiently target the right healthcare professionals.

“D-PLEX₁₀₀ is a differentiated therapy addressing an important unmet need, and we are excited to partner with PolyPid to help bring it to patients in the United States and Canada, if approved,” said Ronald Scarboro, Chief Executive Officer of Azurity Pharmaceuticals. “Our commercial model was built to support specialized therapies like this - connecting the right treatment to the right healthcare professionals and patients through efficient, focused execution.”

A key element of this strategic fit lies in Azurity’s recent market activity. In late 2025, the company acquired Sebela Pharmaceuticals' bowel-preparation franchise. These products are used by gastroenterologists and colorectal surgeons prior to procedures—the very same specialists who will be the primary prescribers of D-PLEX₁₀₀ for its initial indication. This existing commercial footprint creates a powerful and efficient channel to market, allowing Azurity to leverage established relationships and workflows to drive adoption.

Charting the Path Forward

With the NDA submission for D-PLEX₁₀₀ completed in June 2026 and FDA acceptance expected next month, the path to market is becoming increasingly clear, with a U.S. launch targeted for the first quarter of 2027, pending regulatory approval.

The partnership also looks to the future, with a framework for expanding D-PLEX₁₀₀'s use. The agreement includes provisions to jointly pursue label expansion into other SSI indications beyond abdominal surgery. Critically, Azurity has committed to funding these future clinical development programs, significantly de-risking PolyPid’s pipeline expansion and maximizing the asset’s long-term value.

By securing a strong North American partner, PolyPid retains full ownership of its global commercial rights outside the U.S. and Canada, as well as its entire Kynatrix platform and associated pipeline assets in areas like oncology and metabolic diseases. The financial stability and market validation from this deal empower the company to pursue these future innovations from a position of unprecedented strength, promising further advancements from its unique drug delivery technology.